INmune Bio Inc.'s SEC filings document the disclosure record of a Nasdaq-listed Nevada biotechnology company developing innate-immune therapies. Its filings identify common stock traded under INMB and cover material-event reports, Regulation FD presentations, shareholder letters, clinical and regulatory updates, operating and financial results, and capital-structure disclosures.
Recent 8-K filings include disclosures tied to product-platform communications and a material definitive agreement involving INmune Bio International and Anthony Nolan for the CORDStrom platform. Proxy materials cover shareholder voting and governance matters, while the company’s formal disclosures frame recurring risks and development-stage issues associated with biotechnology research, regulatory pathways, collaborations and financing.
INmune Bio Inc. reported that it has submitted a scientific manuscript for peer review describing results from its Phase 2 MINDFuL trial in early Alzheimer’s disease with inflammation. The manuscript, titled “XPro1595, a Selective Soluble TNF Neutralizer, in Early Alzheimer’s Disease with Inflammation (ADi): Results from the Phase 2 MINDFuL Trial,” was submitted to npj Dementia, a Nature Portfolio journal. The company furnished a press release about this submission as an exhibit to the report.
INmune Bio (INMB) Form 3: Cory Randall Ellspermann, listed as a director and Interim CFO, reported beneficial ownership of stock options totaling 245,000 shares. The filing lists five option grants exercisable on dates between 11/24/2029 and 12/04/2034 with exercise prices from $3.91 to $21.06. One option is noted as fully vested and other grants include stated vesting schedules.
Highbridge Capital Management, LLC reported beneficial ownership of 1,454,400 shares of Inmune Bio, Inc. common stock that are issuable upon exercise of warrants. That amount represents 5.2% of the company's outstanding common stock on a base of 26,585,258 shares as stated in the issuer's prospectus, and the filing clarifies these shares are held by Highbridge-managed funds. The filing identifies Highbridge as a Delaware investment adviser and reports sole voting and dispositive power over the 1,454,400 shares. The statement asserts the securities were acquired in the ordinary course of business and not for the purpose of influencing control.
INmune Bio Inc. disclosure shows two reporting persons—CVI Investments, Inc. and its investment manager Heights Capital Management, Inc.—beneficially hold 1,396,279 shares represented by warrants. Those shares equal 4.9% of the outstanding common stock based on 26,585,258 shares reported outstanding as of June 30, 2025. The warrants include an anti-exercise limitation that prevents exercise to the extent ownership would exceed 4.99%.
The filing states neither reporting person has sole voting or dispositive power; voting and disposition are shared. Heights serves as investment manager to CVI and may exercise voting and dispositive power over the shares held by CVI, while each party disclaims beneficial ownership except for pecuniary interest.
Inmune Bio's Schedule 13G/A shows Praetorian-related entities holding disclosed positions in the company's common stock. Praetorian Capital Fund LLC directly beneficially owns 771,200 shares—comprised of 180,800 shares issuable upon warrants and 590,400 shares underlying call options exercisable within 60 days—representing approximately 2.9% of the class based on 26,585,258 shares outstanding. Mongolia (Barbados) Corp. directly owns 150,000 shares underlying call options (about 0.6%), and Harris Kupperman may be deemed to beneficially own a combined 921,200 shares (about 3.4%).
The filing identifies the reporting persons' roles (investment manager, manager, controlling person) and disclaims beneficial ownership beyond direct holdings. It specifies that reported positions include instruments exercisable within 60 days and includes a certification that the securities were not acquired to change or influence control of the issuer.